filmov
tv
Emerging Treatments in Schizophrenia
Показать описание
All currently available medications for schizophrenia derive their efficacy from blockade of dopaminergic receptors, a mechanism of action that leaves many symptoms unresolved and is associated with a significant side effect burden. Here, the experts briefly discuss the challenge of treating schizophrenia with the current medications and explore 4 new drugs (ulotaront, KarXT, CVL-231, and pimavanserin) that approach treatment of schizophrenia using different neural pathways.
#psychiatrist #psychiatry #schizophrenia #psychosis
This video is a publicly available educational resource provided by Sunovion Pharmaceuticals Inc. It was produced prior to and independent of the JCP InfoPack “Emerging Treatments in Schizophrenia.”
- - - -
Presented by The Journal of Clinical Psychiatry and supported by Sunovion Pharmaceuticals Inc.
Christoph U. Correll, MD, Chair of the teleconference, is affiliated with the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; and Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
Anissa Abi-Dargham, MD, is affiliated with the Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, New York
Oliver Howes, MRCPsych, PhD, is affiliated with Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK
#psychiatrist #psychiatry #schizophrenia #psychosis
This video is a publicly available educational resource provided by Sunovion Pharmaceuticals Inc. It was produced prior to and independent of the JCP InfoPack “Emerging Treatments in Schizophrenia.”
- - - -
Presented by The Journal of Clinical Psychiatry and supported by Sunovion Pharmaceuticals Inc.
Christoph U. Correll, MD, Chair of the teleconference, is affiliated with the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; and Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
Anissa Abi-Dargham, MD, is affiliated with the Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, New York
Oliver Howes, MRCPsych, PhD, is affiliated with Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK
Комментарии